Complex Regional Pain Syndrome Clinical Trial
Official title:
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 as an Adjunctive Therapy in Adult Subjects With Chronic Complex Regional Pain Syndrome
The purpose of this study is to investigate the effect of soticlestat (TAK-935) on calculated 24-hour average pain intensity by the numeric pain scale (NPS).
The drug being tested in this study is called soticlestat (TAK-935). Soticlestat is being tested to treat people with chronic complex regional pain syndrome (CRPS). This study will look at the efficacy, safety, and tolerability of soticlestat as an adjunctive therapy in participants with CRPS. The study will enroll approximately 24 patients. Participants will be randomly assigned (by chance, like flipping a coin) in 2:1 ratio to one of the two treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need): Soticlestat 100 mg tablets, 100, 200 or 300 mg twice daily (BID) Placebo (dummy inactive pill) - this is a tablet that looks like the study drug but has no active ingredient Participants will receive 100 mg soticlestat tablets or soticlestat matching placebo tablets, BID for Week 1, 2x100 mg soticlestat tablets or soticlestat matching placebo tablets, BID for Week 2 and followed by 3x100 mg soticlestat tablets or soticlestat matching placebo tablets, BID for Week 3. Dose will be uptitrated based on safety and tolerability in titration period. Participants will continue to receive the same dose in maintenance period. Dose adjustments during maintenance period may take place due to safety and tolerability. Participants will then enter Part B (optional) or taper period. In Part B all participants will receive soticlestat 2x100 mg tablets, BID for 1 Week, followed by soticlestat 3x100 mg tablets, BID for 1 Week. Dose will be uptitrated/downtitrated based on safety and tolerability in titration period (Part B), participants will continue to receive the same dose in maintenance period (Part B) and followed by a taper period. This multi-center trial will be conducted in United Kingdom. The overall time to participate in this study is approximately 36 weeks. Participants will make multiple visits to the clinic and will be contacted by telephone 15 days after last dose of study drug for a follow-up assessment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02753335 -
A Comparison of Two Treatments for CRPS and Changes in Resting-State Connectivity of Cerebral Networks.
|
N/A | |
| Recruiting |
NCT01134289 -
Analysis of Photoplethysmographic Signal in Lumbar Sympathetic Block
|
Phase 3 | |
| Completed |
NCT00579085 -
Double Blind Placebo Controlled Study of Outpatient Intravenous Ketamine for the Treatment of CRPS
|
Phase 2 | |
| Completed |
NCT02837822 -
Effects of Spinal Cord Stimulation on Sensory Perceptions of Chronic Pain Patients
|
N/A | |
| Completed |
NCT02070367 -
Somatosensory Assessment and Rehabilitation of Allodynia (SARA)
|
N/A | |
| Completed |
NCT00462566 -
The Efficacy of Motor Cortex Stimulation for Pain Control
|
N/A | |
| Active, not recruiting |
NCT03228160 -
Light Irradiation and Outcome for Neuropathic Pain
|
N/A | |
| Terminated |
NCT02094352 -
Randomized Controlled Trial of Ketamine Infusion With Continuous Epidural Infusion for Treatment of Complex Regional Pain Syndrome
|
Phase 2 | |
| Recruiting |
NCT06306157 -
Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome
|
Phase 4 | |
| Recruiting |
NCT02502162 -
Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome
|
N/A | |
| Recruiting |
NCT06393101 -
The Effects and Mechanisms of a High CBD Cannabis Extract (BRC-002) for the Treatment of Pain and Health in Complex Regional Pain Syndrome
|
Phase 1 | |
| Recruiting |
NCT03616262 -
"Efficacy of Botulinum Toxin Injection in Reducing Limb Pain in Patients With Complex Regional Pain Syndrome"
|
Early Phase 1 | |
| Active, not recruiting |
NCT02504008 -
CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1
|
Phase 3 | |
| Completed |
NCT03879538 -
Nitrous Oxide for the Treatment of Complex Regional Pain Syndrome
|
Phase 3 | |
| Terminated |
NCT03794024 -
Comparison of Dorsal Column Stimulation to Dorsal Root Ganglion Stimulation for Complex Regional Pain Syndrome
|
||
| Terminated |
NCT00780390 -
Autonomic Dysfunction and Spinal Cord Stimulation in Complex Regional Pain Syndrome
|
N/A | |
| Completed |
NCT00904202 -
A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions
|
Phase 4 | |
| Recruiting |
NCT05197959 -
Treatment of Complex Regional Pain Syndrome
|
N/A | |
| Completed |
NCT02753101 -
[18F]FTC-146 PET/MRI in Healthy Volunteers and in CRPS and Sciatica
|
Early Phase 1 | |
| Withdrawn |
NCT00414804 -
Spinal Cord Stimulation Versus Nerve Blocks and Physical Therapy
|
N/A |